• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

02.11.2017

Teva Announces Completion of Plan B One-Step® Divestiture to Foundation Consumer Healthcare

Teva to receive $675 million cash proceeds to progress repayment of term loan debt JERUSALEM--(BUSINESS WIRE)--Nov. 2, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the sale of Plan B One-Step® and Teva’s value brands of emergency contraception to Foundation Consumer Healthcare in a $675 million cash transaction. “Today’s announcement, coupled with the recent completion of the sale of PARAGARD®, exhibits Teva’s commitment to divest non-core businesses to ensure that we are even more focused and efficient in this rapidly changing and highly-competitive environ...
02.11.2017

Teva Reports Third Quarter 2017 Financial Results

Revenues of $5.6 billion Cash flow from operations of $1.1 billion GAAP EPS of $0.52 Non-GAAP EPS of $1.00 Teva announces third quarter 2017 dividend of 8.5 cents 2017 outlook revised to non-GAAP EPS of $3.77 - $3.87 JERUSALEM--(BUSINESS WIRE)--Nov. 2, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2017. Revenues in the third quarter of 2017 were $5.6 billion, up 1% compared to the third quarter of 2016. Excluding the impact of foreign ...
01.11.2017

Teva Announces Completion of PARAGARD® Divestiture to CooperSurgical

Teva receives $1.1 billion cash proceeds to progress repayment of term loan debt Closures mark first completion of planned divestiture of non-core assets to enable greater focus on core Specialty therapeutic areas of CNS and Respiratory JERUSALEM--(BUSINESS WIRE)--Nov. 1, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the divestiture of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical in a $1.1 billion cash transaction. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively. “W...
31.10.2017

Teva Wins Generic Uceris® Patent Trial

JERUSALEM--(BUSINESS WIRE)--Oct. 31, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the United States District Court for the District of Delaware has ruled in the Company’s favor in patent litigation involving Teva’s abbreviated new drug application (ANDA) directed to a generic version of Valeant’s Uceris® (budesonide ER) tablets. At trial in May, the Court found that Plaintiffs did not meet the threshold to establish infringement, and the Court has now issued its written decision confirming that Teva’s ANDA product does not infringe the asserted patent. “We are pleased to ha...
30.10.2017

Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017

JERUSALEM--(BUSINESS WIRE)--Oct. 30, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Kåre Schultz will join the Company as President and Chief Executive Officer, effective November 1, 2017. As previously announced on September 11, 2017, Mr. Schultz succeeds Dr. Yitzhak Peterburg, who is serving as Interim Chief Executive Officer. “Kåre Schultz joining is the start of a new chapter at Teva,” said Dr. Sol J. Barer, Chairman of Teva’s Board of Directors. “Kåre has extensive global pharmaceutical experience and a strong track record in corporate turnarounds, as well as in driving growth a...
26.10.2017

Teva to Highlight Asthma Data at the 2017 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

Presentations Span Teva’s Respiratory Portfolio – including Rescue, Maintenance Inhalers and Biologic Asthma Treatment JERUSALEM--(BUSINESS WIRE)--Oct. 26, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that five company-sponsored abstracts will be presented at the 2017 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Boston, October 26-30, 2017. Among the accepted abstracts, data from two analyses examined the efficacy of CINQAIR® IV (reslizumab) Injection, a humanized interleukin-5 antagonist monoclonal antibody for the treatment of severe ...
19.10.2017

Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS – ACTRIMS Congress in Paris

JERUSALEM--(BUSINESS WIRE)--Oct. 19, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on its multiple sclerosis (MS) program, including COPAXONE® (glatiramer acetate injection), a product for relapsing forms of MS, and laquinimod, an investigational MS therapy, will be highlighted in 11 presentations at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in Paris, October 25-28, 2017. “New data from Teva’s MS program further contributes to t...
17.10.2017

Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA

Key milestone reached for Teva to advance global fremanezumab program for the preventive treatment of migraine Fremanezumab aims to address unmet need in migraine community, a disease with currently limited preventive therapeutic options JERUSALEM--(BUSINESS WIRE)--Oct. 17, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. “The BLA s...
10.10.2017

Teva to Report Third Quarter 2017 Financial Results on November 2, 2017

JERUSALEM--(BUSINESS WIRE)--Oct. 10, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2017 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-869-2321; Canada 1-866-766-8269 or Internation...
05.10.2017

Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy

Best oral presenter Dr. Olga Salamero chosen as the tomy’s winner. Research focused on treatments in elderly APL patients AMSTERDAM--(BUSINESS WIRE)--Oct. 5, 2017-- Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the winner of the tomy’s (Teva’s Orphan hematological Malignancies award for Young hematologists) at the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy last week. During the event entitled, ‘Next-Generation APL Leaders: Teva’s Award for Young Hematologists’ Dr. Salamero was awarded a tomy’s trophy, as well as a bursary to attend the 2017 American Society of Hematology...